You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Congresses

Congress Materials

Access abstracts, posters, and presentations presented at the following congresses

October 2021

German, Austrian, and Swiss Societies for Hematology & Medical Oncology (DGHO)

September 2021

Society of Hematologic Oncology (SOHO)

September 2021

Hematology Society of Australia and New Zealand (Blood)

September 2021

European Society for Medical Oncology (ESMO)

European Society for Medical Oncology (ESMO)

September 2021 (Virtual)
September 2021

International Workshop on CLL (iwCLL)

September 2021

Chinese Society of Clinical Oncology (CSCO)

Chinese Society of Clinical Oncology (CSCO)

September 2021 (Virtual)

Abstracts

A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high/mismatch repair-deficient solid tumors A phase II study of the efficacy and safety of tislelizumab plus lenvatinib in patients with advanced or metastatic hepatocellular carcinoma: results of safety run-in period First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma Phase 2 study of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA study) Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma RATIONALE-307: tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65 years Results from RATIONALE 303: a global phase 3 study of tislelizumab (TIS) vs docetaxel (TAX) as second- or third-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1-refractory/resistant unresectable or metastatic melanoma from a phase 1b study Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with advanced platinum-resistant ovarian cancer (PROC) Tislelizumab (BGB-A317) for relapsed/refractory classical Hodgkin lymphoma: long-term follow-up efficacy and safety results from a phase 2 study Zanidatamab (ZW25), a novel anti-HER2 bispecific antibody, monotherapy as second-line treatment for patients (pts) with advanced or metastatic HER2-amplified biliary tract cancer (BTC): a phase 2b trial-in-progress Zanubrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: 34-month follow-up results
September 2021

French Society of Hematology (SFH)

September 2021

World Congress on Lung Cancer (WCLC)

September 2021

Polish Society of Hematology and Transfusion Medicine (PTHiT)

August 2021

Pan Pacific Lymphoma Conference (PPLC)

July 2021

International Symposium of Yonsei Song-dang Institute for Cancer Research (N/A)

International Symposium of Yonsei Song-dang Institute for Cancer Research (N/A)

July 2021 (Seoul, South Korea)
June 2021

World Congress on Gastrointestinal Cancer (WCGI)

June 2021

International Conference on Malignant Lymphoma (ICML)

June 2021

European Hematology Association (EHA)

European Hematology Association (EHA)

June 2021 (Virtual)
June 2021

American Society of Clinical Oncology (ASCO)

American Society of Clinical Oncology (ASCO)

June 2021 (Virtual)

Posters

A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutation A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable or metastatic microsatellite instability-high/mismatch repair deficient solid tumors ADVANTIG-105: phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors AdvanTIG-202: a phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer AdvanTIG-203: a randomized phase 2 study comparing anti-TIGIT monoclonal antibody ociperlimab plus tislelizumab vs tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma expressing programmed death-ligand 1 (PD-L1) AdvanTIG-302: anti-TIGIT monoclonal antibody ociperlimab plus tislelizumab vs pembrolizumab in programmed death ligand 1-selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer Efficacy and safety of zanubrutinib versus rituximab-based chemotherapy in Waldenstrӧm macroglobulinemia (WM): matching-adjusted indirect comparisons PARALLEL 303: phase 2 randomized study of pamiparib vs placebo as maintenance therapy in patients with inoperable locally advanced or metastatic gastric cancer that responded to platinum-based first-line chemotherapy RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma RATIONALE-307: tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65 The effects of tislelizumab treatment on the health-related quality of life of non−small cell lung cancer patients who progressed on a prior platinum-containing regimen Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: a phase 1B/2 trial-in-progress

Abstracts

A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutation A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable or metastatic microsatellite instability-high/mismatch repair deficient solid tumors AdvanTIG-105: phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors AdvanTIG-202: a phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer AdvanTIG-203: a randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab vs tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1) AdvanTIG-302: anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) vs pembrolizumab (PEM) in programmed death ligand 1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) Cardiac risk factors and adverse events among patients receiving first-line CLL treatment in a real-world community practice setting Cost-effectiveness of zanubrutinib versus ibrutinib in adult patients with Waldenström macroglobulinemia in the United States Efficacy and safety of zanubrutinib versus rituximab-based chemoimmunotherapy in Waldenström macroglobulinemia (WM): matching-adjusted indirect comparisons PARALLEL 303: phase 2 randomized study of pamiparib vs placebo as maintenance therapy in patients (pts) with inoperable locally advanced or metastatic gastric cancer that responded to platinum-based first-line (1L) chemotherapy Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma RATIONALE-307: tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65 Real-world treatment patterns, adherence, costs and healthcare resource utilization associated with Waldenström macroglobulinemia in the United States The effects of tislelizumab treatment on the health-related quality of life of non-small cell lung cancer patients who progressed on a prior platinum-containing regimen Tislelizumab (BGB-A317) for relapsed/refractory (R/R) classical hodgkin lymphoma (cHL): long-term follow-up efficacy and safety results from a phase 2 study Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: a phase 1B/2 trial-in-progress
May 2021

International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

April 2021

American Association for Cancer Research (AACR)

March 2021

European Lung Cancer Congress (ELCC)

March 2021

Japanese Gastric Cancer Association (JGCA)

January 2021

American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (ASCO-GI)

December 2020

European Society of Medical Oncology Immuno-Oncology (ESMO-IO)

European Society of Medical Oncology Immuno-Oncology (ESMO-IO)

December 2020 (Virtual)
December 2020

American Society of Hematology (ASH)

American Society of Hematology (ASH)

December 2020 (Virtual)
November 2020

Society for Neuro - Oncology (SNO)

November 2020

International Society for Pharmacoeconomics and Outcomes Research - Europe (ISPOR-EU)

November 2020

Society for Immunotherapy of Cancer (SITC)

Society for Immunotherapy of Cancer (SITC)

November 2020 (Virtual)
October 2020

North America Conference on Lung Cancer (NACLC)

September 2020

Chinese Society of Clinical Oncology (CSCO)

Chinese Society of Clinical Oncology (CSCO)

September 2020 (Virtual)

Abstracts

ASPEN: results of a phase 3 randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM) Neoadjuvant tislelizumab or placebo plus platinum-based chemotherapy followed by adjuvant tislelizumab or placebo in patients with resectable non‑small cell lung cancer (NSCLC): a phase 3 trial in progress Phase 3 trial in progress: tislelizumab plus cisplatin/carboplatin and gemcitabine versus placebo plus cisplatin/carboplatin and gemcitabine in Chinese patients with advanced urothelial carcinoma Phase 3 trial in progress: tislelizumab vs placebo in combination with concurrent chemoradiotherapy (cCRT) in patients with localized esophageal squamous cell carcinoma (ESCC) Platinum-containing combination chemotherapy with or without tislelizumab as first-line therapy in patients with extensive-stage small cell lung cancer: A phase 3 trial in progress RATIONALE 304: tislelizumab + chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous non-small cell lung cancer (nsq-NSCLC) RATIONALE 307: phase 3 study of tislelizumab plus chemotherapy vs chemotherapy alone as first‑line (1L) treatment for advanced squamous non‑small cell lung cancer (sq NSCLC) Tislelizumab + chemotherapy versus placebo + chemotherapy in Chinese patients with recurrent or metastatic nasopharyngeal cancer: a phase 3 trial-in-progress Tislelizumab in Chinese patients with non-small cell lung cancer (NSCLC) Tislelizumab plus standard chemotherapy and health-related quality of life In patients with advanced squamous non-small cell lung cancer Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type (MYD88WT) Waldenström macroglobulinemia (WM) Zanubrutinib (BGB-3111) in combination with rituximab in patients with relapsed/refractory non-Hodgkin lymphoma Zanubrutinib monotherapy for patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma: results from a phase 2, single-arm, multicenter, study
September 2020

European Society for Medical Oncology (ESMO)

European Society for Medical Oncology (ESMO)

September 2020 (Virtual)
September 2020

Association of VA Hematology/Oncology (AVAHO)

July 2020

World Congress on Gastrointestinal Cancer (WCGI)

June 2020

American Association for Cancer Research (AACR)

June 2020

European Hematology Association (EHA)

European Hematology Association (EHA)

June 2020 (Virtual)
May 2020

American Society of Clinical Oncology (ASCO)

American Society of Clinical Oncology (ASCO)

May 2020 (Virtual)

Abstracts

ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM) Association between immune and tumor gene signatures with response or resistance to tislelizumab monotherapy or in combination with chemotherapy in gastroesophageal adenocarcinoma BGB-A425, an investigational anti-TIM-3 monoclonal antibody, in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: A phase I/II trial in progress Immune- and tumor-intrinsic gene expression profiles of response or resistance to tislelizumab as monotherapy or in combination with chemotherapy in non-small cell lung cancer (NSCLC) Phase 3 study of tislelizumab plus chemotherapy vs chemotherapy alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC) Three-year follow-up of treatment-naïve and previously treated patients with Waldenström macroglobulinemia (WM) receiving single-agent zanubrutinib Trial in progress: A phase III, randomized, open-label study comparing zanubrutinib plus rituximab versus bendamustine plus rituximab in patients with previously untreated mantle cell lymphoma (MCL) Trial in progress: a phase II, multicenter, single-arm study of zanubrutinib (BGB-3111) in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma intolerant of prior treatment with ibrutinib Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type (MYD88WT) Waldenström macroglobulinemia (WM) ZW25, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress. Zanubrutinib monotherapy for patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma: results from a phase II, single-arm, multicenter, study
May 2020

International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

February 2020

American Society of Clinical Oncology - Genitourinary Cancers Symposium (ASCO-GU)

January 2020

American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (ASCO-GI)

December 2019

European Society for Medical Oncology-Immuno Oncology (ESMO-IO)

December 2019

American Society of Hematology (ASH)

American Society of Hematology (ASH)

December 2019 (Orlando, FL, United States)

Abstracts

A quantitative systems pharmacology (qsp) model to predict receptor occupancy of Bruton's tyrosine kinase (BTK) inhibitors in peripheral blood mononuclear cells, bone marrow and lymph nodes of patients with B-cell malignancies ALPINE: phase 3 trial of zanubrutinib (BGB-3111) vs ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) An update on safety and preliminary efficacy of highly specific Bruton tyrosine kinase (BTK) inhibitor zanubrutinib in combination with PD-1 inhibitor tislelizumab in patients with previously treated B-cell lymphoid malignancies BTK Leu528Trp - a potential secondary resistance mechanism specific for patients with chronic lymphocytic leukemia treated with the next generation BTK inhibitor zanubrutinib Efficacy and safety of zanubrutinib in patients with treatment-naive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): initial results from Arm C of the SEQUOIA (BGB-3111-304) trial Exposure-response relationship of the Bruton tyrosine kinase inhibitor, zanubrutinib (BGB-3111) in patients with hematologic malignancies Phase 2 study of zanubrutinib (BGB-3111) in patients with relapsed/refractory marginal zone lymphoma Randomized phase 2 zanubrutinib (BGB-3111) + obinutuzumab vs obinutuzumab monotherapy in patients with relapsed/refractory follicular lymphoma (R/R FL) Treatment with the Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrates high overall response rate and durable responses in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): updated results from a phase 1/2 trial
November 2019

European Society for Medical Oncology-Asia (ESMO-Asia)

November 2019

Society for Neuro-Oncology (SNO)

November 2019

International Society for Pharmacoeconomics and Outcomes Research-Europe (ISPOR-EU)

September 2019

International Workshop on CLL (iwCLL)

September 2019

Chinese Society of Clinical Oncology (CSCO)

Chinese Society of Clinical Oncology (CSCO)

September 2019 (Xiamen, Fugian, China)

Posters

A phase 2 trial in progress to evaluate the efficacy and safety of tislelizumab in Chinese patients with previously treated locally advanced unresctable or metastatic solid tumors with microsatellite instablity-high or mismatch repair deficiency A phase 3 trial In progress of platinum-containing combination chemotherapy with or without tislelizumab as first-line therapy in patients with untreated extensive-stage small cell lung cancer Dose escalation of pamiparib in Chinese patients with high-hrade non-mucinous ovarian cancer or advanced triple-negative breast cancer Pamiparib, an investigational PARP 1/2 inhibitor, for the treatment of patients with HER2-negative metastatic breast cancer harboring germline BRCA 1/2 mutations: an open-label, multicenter, phase 2 trial in China Phase 2 study of zanubrutinib (BGB-3111) in patients with relapsed/refractory marginal zone lymphoma (R/R MZL) The molecular binding mechanism of tislelizumab, an investigational anti-PD-1 antibody, is differentiated from pembrolizumab and nivolumab Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (FG/GEJ) adenocarcinoma: RATIONALE 305 Tislelizumab versus placebo in combination with concurrent chemoradiotherapy in patients with localized esophageal squamous cell carcinoma: a phase 3 trial in progress Zanubrutinib for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) Zanubrutinib, a highly specific BTK inhibitor in Chinese patients with relapsed/refractory B cell malignancies: follow up report of a phase 1 trial in China

Abstracts

A phase 1B study to assess safety, tolerability, pharmacokinetics, and preliminary antitumor activity of sitravatinib in combination with tislelizumab in patients (pts) with advanced solid tumors A phase 2 trial in progress to evaluate the efficacy and safety of tislelizumab in Chinese patients with previously treated locally advanced unresectable or metastatic solid tumors with microsatellite instability-high or mismatch repair deficiency A phase 3 trial in progress comparing tislelizumab plus chemotherapy with placebo plus chemotherapy in Chinese patients with recurrent or metastatic nasopharyngeal cancer Dose escalation of pamiparib in Chinese patients with high-grade non-mucinous ovarian cancer (HGOC) or advanced triple-negative breast cancer (TNBC) Pamiparib, an investigational PARP1/2 inhibitor, for the treatment of patients with HER2-negative metastatic breast cancer harboring germline BRCA 1/2 mutations: an open-label, multicenter, phase 2 trial in China Phase 2 study of zanubrutinib (BGB-3111) in patients with relapsed/refractory marginal zone lymphoma (R/R MZL) Phase 3 study comparing tislelizumab in combination with cisplatin/carboplatin + gemcitabine with placebo in combination with cisplatin/carboplatin + gemcitabine as treatment for Chinese patients with advanced urothelial carcinoma: a trial in progress Phase 3 trial in progress of platinum-containing combination chemotherapy with or without tislelizumab as first-line therapy in patients with untreated extensive-stage small cell lung cancer (SCLC) RATIONALE 306: A randomized, placebo-controlled, double-blind trial in progress of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma Safety and efficacy in patients with long-term exposure (LTE) to tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human phase 1 study The molecular binding mechanism of tislelizumab, an investigational anti-PD-1 antibody, is differentiated from pembrolizumab and nivolumab Tislelizumab (BGB-A317) for relapsed/refractory classical Hodgkin lymphoma: updated follow-up efficacy and safety results from a phase 2 study Tislelizumab in Chinese patients (pts) with esophageal cancer (EC), gastric cancer (GC), hepatocellular carcinoma (HCC), and microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) tumors Tislelizumab in Chinese patients (pts) with non-small cell lung cancer (NSCLC) and nasopharyngeal carcinoma (NPC) Tislelizumab in Chinese patients with melanoma, urothelial carcinoma (UC), and renal cell carcinoma (RCC) Tislelizumab in combination with chemotherapy as treatment for Chinese patients with esophageal squamous cell carcinoma (ESCC) Tislelizumab plus chemotherapy as first-line treatment for Chinese patients with lung cancer Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: RATIONALE 305 Tislelizumab versus placebo in combination with concurrent chemoradiotherapy in patients with localized esophageal squamous cell carcinoma (ESCC): A phase 3 trial in progress Zanubrutinib for patients with relapsed or refractory chronic lymphocytic leukemia Zanubrutinib in patients with relapsed/refractory mantle cell lymphoma Zanubrutinib, a highly specific BTK inhibitor in Chinese patients with relapsed/refractory B-cell malignancies: follow-up report of a phase 1 trial in China
September 2019

World Congress on Lung Cancer (WCLC)

September 2019

European Society for Medical Oncology (ESMO)

European Society for Medical Oncology (ESMO)

September 2019 (Barcelona, Spain)
June 2019

International Conference on Malignant Lymphoma (ICML)

June 2019

European Hematology Association (EHA)

May 2019

American Society of Clinical Oncology (ASCO)

American Society of Clinical Oncology (ASCO)

May 2019 (Chicago, IL, United States)

Abstracts

A phase 3 trial-in-progress comparing tislelizumab plus chemotherapy with placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma A randomized, placebo-controlled, phase 3 trial-in-progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma (ESCC) ALPINE: Phase III zanubrutinib (BGB-3111) versus ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Current treatment patterns and associated outcomes in Waldenström macroglobulinemia (WM) and related hematologic malignancies: a systematic literature review (SLR) Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) and a circulating tumor cell (CTC) homologous recombination deficiency (HRD) phenotype or BRCA defects: A trial in progress Phase 2 study of zanubrutinib (BGB-3111) in patients with relapsed/refractory marginal zone lymphoma (R/R MZL) Preliminary results with tislelizumab, an investigational anti-PD-1 antibody, in Chinese patients with nasopharyngeal cancer (NPC) Randomized phase 2 zanubrutinib (BGB-3111) + obinutuzumab (obi) vs obi monotherapy in patients (pts) with relapsed/refractory follicular lymphoma (R/R FL) Tislelizumab, an investigational anti-PD-1 antibody, combined with chemotherapy as first-line treatment for lung cancer in Chinese patients
May 2019

International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

March 2019

American Association for Cancer Research (AACR)

February 2019

American Society of Clinical Oncology - Genitourinary Cancers Symposium (ASCO-GU)

January 2019

American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (ASCO-GI)

December 2018

European Society for Medical Oncology-Immuno Oncology (ESMO-IO)

December 2018

American Society of Hematology (ASH)

November 2018

Society for Neuro-Oncology (SNO)

October 2018

European Society for Medical Oncology (ESMO)

European Society for Medical Oncology (ESMO)

October 2018 (Munich, Germany)
October 2018

International Workshop for Waldendrom's macroglobulinemia (IWWM)

September 2018

World Congress on Lung Cancer (WCLC)

September 2018

Chinese Society of Clinical Oncology (CSCO)

Chinese Society of Clinical Oncology (CSCO)

September 2018 (Xiamen, Fugian, China)

Abstracts

A phase 3, open-label, multicenter, randomized study to investigate the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus docetaxel in patients with non-small cell lung cancer who have progressed on a prior platinum-containing regimen A phase 3, randomized, double-blind, placebo-controlled, multicenter trial of maintenance treatment with pamiparib versus placebo in chinese patients with platinum-sensitive recurrent ovarian cancer A phase 3, randomized, open-label study to compare the efficacy of tislelizumab versus chemotherapy as second-line therapy for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC) An open-label, multicenter, phase 2 study to evaluate the antitumor activity and safety of pamiparib in the treatment of metastatic HER2-negative breast cancer patients with BRCA mutation in China Clinical profile of tislelizumab in Chinese patients with microsatellite instability high (MSI-H) or mismatch repair-deficient (MMRd) solid tumors: preliminary results from an indication-expansion cohort Global phase 3 study of tislelizumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma: A trial-in-progress Pamiparib, a novel PARP 1/2 inhibitor monotherapy for patients with recurrent ovarian, fallopian, and primary peritoneal cancer with germline BRCA mutations: an open-label, multicenter, phase 2 trial in China Phase 2 study of tislelizumab, an anti-programmed cell death receptor-1 antibody, in patients with unresectable hepatocellular carcinoma: trial-in-progress Preliminary results with tislelizumab in Chinese patients with non-small cell lung cancer (NSCLC) Tislelizumab combined with chemotherapy as first-line treatment in Chinese patients (pts) with advanced lung cancer Zanubrutinib, a highly specific BTK inhibitor in Chinese patients with relapsed/refractory B-cell malignancies: initial report of a phase 1 trial in China
September 2018

International Liver Cancer Association (ILCA)

August 2018

Medical Oncology Group of Australia (MOGA)

July 2018

Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE)

June 2018

World Congress on Gastrointestinal Cancer (WCGI)

June 2018

European Hematology Association (EHA)

June 2018

American Society of Clinical Oncology (ASCO)

American Society of Clinical Oncology (ASCO)

June 2018 (Chicago, IL, United States)
April 2018

American Association for Cancer Research (AACR)

February 2018

American Society of Clinical Oncology - Genitourinary Cancers Symposium (ASCO-GU)

January 2018

American Society of Clinical Oncology Clinical Immuno-Oncology Symposium (ASCO-SITC)

December 2017

American Society of Hematology (ASH)

September 2017

Chinese Society of Clinical Oncology (CSCO)

September 2017

International Liver Cancer Association (ILCA)

September 2017

European Society for Medical Oncology (ESMO)

European Society for Medical Oncology (ESMO)

September 2017 (Madrid, Spain)
June 2017

World Congress on Gastrointestinal Cancer (WCGI)

June 2017

International Conference on Malignant Lymphoma (ICML)

June 2017

American Society of Clinical Oncology (ASCO)

April 2017

American Association for Cancer Research (AACR)

March 2017

American Society of Hematology Asia Pacific (ASH-Asia Pacific)